Výsledky vyhledávání - "Rosanne Veerman"

Akademický článek

A bispecific CD40 agonistic antibody allowing for antibody-peptide conjugate formation to enable cancer-specific peptide delivery, resulting in improved T Cell proliferation and anti-tumor immunity in mice

Autor: Aman Mebrahtu, Ida Laurén, Rosanne Veerman, Gözde Güclüler Akpinar, Martin Lord, Alexandros Kostakis, Juan Astorga-Wells, Leif Dahllund, Anders Olsson, Oscar Andersson, Jonathan Persson, Helena Persson, Pierre Dönnes, Johan Rockberg, Sara Mangsbo

Publikováno v: Nature Communications, Vol 15, Iss 1, Pp 1-20 (2024)

Abstract Current antibody-based immunotherapy depends on tumor antigen shedding for proper T cell priming. Here we select a novel human CD40 agonistic drug candidate and generate a bispecific antibody, herein named BiA9*2_HF, that allows for rapid an

Externí odkaz: https://doaj.org/article/d469af897715422a9a5f977bb3bd08a2

Zobrazit plný text záznamu

Abstract 2929: Modular peptide cargo delivery by targeting CD40 enables ligandome driven, precision immunotherapy via the Adaptable Drug Affinity Conjugate (ADAC™) technology

Autor: Aman Mebrahtu, Ida Lauren, Rosanne Veerman, Alexandros Kostakis, Gözde Gucluler Akpinar, Oskar Andersson, Lindvi Gudmundsdotter, Tina Furebring, Helena Persson, Pierre Donnes, Johan Rockberg, Sara Mangsbo

Publikováno v: Cancer Research. 83:2929-2929

Agonistic anti-CD40 therapy has shown impressive efficacy in preclinical murine models, models inert to toxicity of high systemic drug exposure. Clinical data consist of pharmacodynamic responses reported as non-specific cytokine release, transient d

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::94e01989b7555bb3b6d0875d90946855
https://doi.org/10.1158/1538-7445.am2023-2929

Zobrazit plný text záznamu

Abstract 2890: The development of an Adaptable Drug Affinity Conjugate (ADAC) targeting CD40 for a flexible therapeutic peptide cargo delivery to dendritic cells

Autor: Ida Laurén, Mohamed Eltahir, Aman Mebrahtu, Rosanne Veerman, Juan Astorga, Aljona Saleh, Jimmy Ytterberg, Annika Lindqvist, Leif Dahllund, Anders Olsson, Oskar Andersson, Johan Rockberg, Helena Persson, Sara Mangsbo

Publikováno v: Cancer Research. 82:2890-2890

CD40 agonistic antibodies targeting antigen-presenting cells rely on simultaneous antigen presentation for optimal efficacy, as the co-stimulatory signal alone will not lead to T cell activation. Herein we have developed a novel Adaptable Drug Affini

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::48740097f60f7227452e564d9b00e3ce
https://doi.org/10.1158/1538-7445.am2022-2890

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání